Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.

ABSTRACTApproximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes(PRO), and clinical data surrounding the dulaglutideadministration device. Dulaglutide1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatideBID, and insulin glargine(in 2 trials), and non-inferiority to liraglutidein reduction of HbA1c from baseline, with an acceptable safety profile. Dulaglutide-treated patients achieved the composite endpoint of an HbA1c <7.0% with no hypoglycemia, no severe hypoglycemia, and no weight gain significantly more than metformin, sitagliptin, exenatideBID or insulin glarginetreated patients. Dulaglutideconsistently showed an early onset of glycemic control, lasting up to 104 w...